Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7937756 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL287541 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL841679 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL31323920 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6822770 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6822769 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL437748 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL288282 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL7935130 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL288281 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| CN-119192296-A | Polypeptide compound, pharmaceutical composition and application | 杭州禾泰健宇生物科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| US-20240197897-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2024-06-20 | — | — | US | claimed |
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | BICYCLETX LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| US-20240108737-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-04-04 | — | — | US | claimed |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-03-14 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117083287-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-0606881-B1 | Cyclic pentapeptides having a beta-turn and a gamma-turn | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC1A3 2430/4885SLC1A2 1491/4885SLC1A1 2314/4885 |
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | TFRC, FTH1, SLC40A1 | SLC1A3 715/4885SLC1A2 1039/4885SLC1A1 605/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | SLC1A3 2356/4885SLC1A2 3631/4885SLC1A1 2376/4885 |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC1A3 2575/4885SLC1A2 3520/4885SLC1A1 2813/4885 |
| US-20240197897-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | KLRK1, TIMCC, MICA | SLC1A3 1240/4885SLC1A2 2754/4885SLC1A1 2151/4885 |
| US-20240108737-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC1A3 2575/4885SLC1A2 3520/4885SLC1A1 2813/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | SLC1A3 1506/4885SLC1A2 1260/4885SLC1A1 880/4885 |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | SLC1A3 1172/4885SLC1A2 1497/4885SLC1A1 1129/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | SLC1A3 686/4885SLC1A2 2178/4885SLC1A1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.